---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-029741"
form_type: "8-K"
ticker: "BCTX"
cik: "0001610820"
company_name: "BriaCell Therapeutics Corp."
filed_at: "2022-10-28T23:59:59+00:00"
generated_at: "2026-06-22T22:42:51.890358+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BriaCell loses foreign private issuer status, restates interim financials to U.S. GAAP

## Summary
- As of July 31, 2022, BriaCell no longer qualifies as foreign private issuer; effective Aug 1, 2022 must file as domestic issuer.
- Restated interim financial statements for Oct 31, 2021, Jan 31, 2022, and Apr 30, 2022 from IFRS to U.S. GAAP.
- Net loss for Q1 FY2022 (Oct 2021) was $27.5M, primarily due to $25.3M warrant remeasurement loss.
- Cash and cash equivalents were $55.5M as of Oct 31, 2021; accumulated deficit $56.7M.
- Company is defending against Alpha Capital Anstalt lawsuit over warrant amendment; believes it will not have to pay.

## SEC filing metadata
- accession: 0001493152-22-029741
- form_type: 8-K
- ticker: BCTX
- cik: 0001610820
- company_name: BriaCell Therapeutics Corp.
- filed_at: 2022-10-28T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610820/000149315222029741/0001493152-22-029741-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610820/000149315222029741/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-029741
- JSON: https://secwatch.observer/filing/0001493152-22-029741.json
- Plain text: https://secwatch.observer/filing/0001493152-22-029741.txt

## Key facts
- Earnings Releases
  BriaCell Therapeutics Corp. reported Three months ended October 31, 2021 results: net income (27,533,485 ), EPS $ (1.81 ).
  - Period: Three months ended October 31, 2021
  - Net income: (27,533,485 )
  - EPS: $ (1.81 )
  - Result: reported results
  source text: : Research and development expenses $ 875,636 $ 149,062 General and administrative expenses 1,409,173 231,309 Total operating expenses 2,284,809 380,371 Operating loss (2,284,809 ) (380,371 ) Financial expenses, net (25,248,676 ) (40,956 ) Loss for the period (27,533,485 ) (421,327 ) Other comprehensive loss - Foreign currency translation adjustment - 35,340 Comprehensive loss for the period $ (27,533,485 ) $ (385,987 ) Net loss per share – basic and diluted $ (1.81 ) $ (0.54 ) Weighted average number of shares used in computing net basic and diluted
  evidence_url: https://www.sec.gov/Archives/edgar/data/1610820/000149315222029741/0001493152-22-029741-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.